Fosun Pharma (02196.HK): Fomaidin initiated Phase III clinical trials for the treatment of pediatric low-grade gliomas in China.

Zhtng Cijng APP News, Fosun Pharma (02196.HK) announced that its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has initiated Phase III clinical trials of Fomepizole (generic name: Luvominepizole tablets, hereinafter referred to as "the drug") for the treatment of pediatric low-grade glioma in China (excluding Hong Kong, Macau, and Taiwan).